Isotype-specific secondary antibodies for improved signal detection
![](/46/pdcnewsitem/07/73/55/Isotype-specific%20secondary%20antibodies%20for%20improved%20signal%20detection-900x400px.jpeg)
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.
Bio-Rad Laboratories has launched its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.
Secondary antibodies are key components of antibody detection systems. The selection of an optimum secondary antibody can improve positive signals in addition to reducing false positive or negative staining. Recombinant monoclonal isotype-specific secondary antibodies detect individual isotypes, without species or isotype cross-reactivity, enabling multiple unlabeled mouse monoclonal antibodies of differing isotypes to be used simultaneously. This obviates the need to source secondary antibodies from other species. The isotype-specific antibodies offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required, for instance, during multiplexing or to prevent nonspecific background staining.
Bio-Rad’s recombinant monoclonal antibodies are generated using the Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures consistent and secure supply.
“Recombinant human monoclonal antibodies are selected against epitopes unique to the isotype and offer significant advantages over traditional secondary antibodies,” said Tracey Long, Bio-Rad Marketing Manager, Life Science Group. “Bio-Rad’s recombinant monoclonal isotype-specific antibodies are easy to use and can be substituted for any secondary in the protocol without the need for extra steps,” she added.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance